JP2017538669A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538669A5 JP2017538669A5 JP2017520986A JP2017520986A JP2017538669A5 JP 2017538669 A5 JP2017538669 A5 JP 2017538669A5 JP 2017520986 A JP2017520986 A JP 2017520986A JP 2017520986 A JP2017520986 A JP 2017520986A JP 2017538669 A5 JP2017538669 A5 JP 2017538669A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- group
- mdsc
- human genetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021102148A JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2023047480A JP2023078398A (ja) | 2014-10-24 | 2023-03-24 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14190370.8 | 2014-10-24 | ||
| EP14190370.8A EP3012271A1 (en) | 2014-10-24 | 2014-10-24 | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| PCT/IB2015/058124 WO2016063233A1 (en) | 2014-10-24 | 2015-10-21 | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021102148A Division JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538669A JP2017538669A (ja) | 2017-12-28 |
| JP2017538669A5 true JP2017538669A5 (enExample) | 2018-11-29 |
| JP6918279B2 JP6918279B2 (ja) | 2021-08-11 |
Family
ID=51868772
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520986A Active JP6918279B2 (ja) | 2014-10-24 | 2015-10-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2021102148A Active JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2023047480A Pending JP2023078398A (ja) | 2014-10-24 | 2023-03-24 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021102148A Active JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2023047480A Pending JP2023078398A (ja) | 2014-10-24 | 2023-03-24 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20170247464A1 (enExample) |
| EP (4) | EP3012271A1 (enExample) |
| JP (3) | JP6918279B2 (enExample) |
| CA (1) | CA2964203C (enExample) |
| DK (2) | DK3209691T3 (enExample) |
| ES (2) | ES2817074T3 (enExample) |
| HU (1) | HUE050318T2 (enExample) |
| PL (2) | PL3209691T3 (enExample) |
| WO (1) | WO2016063233A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| ES2894335T5 (es) | 2015-08-26 | 2024-06-27 | Univ Leland Stanford Junior | Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune |
| DK4186927T3 (da) * | 2015-10-21 | 2025-06-10 | Ose Immunotherapeutics | Fremgangsmåder og sammensætninger til at ændre makrofagers polarisering til pro-inflammatoriske celler til behandling af kræft |
| PH12018550160B1 (en) | 2016-04-14 | 2024-07-03 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| WO2018008470A1 (ja) * | 2016-07-05 | 2018-01-11 | 国立大学法人神戸大学 | 抗腫瘍剤 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| CN110325549B (zh) | 2016-12-09 | 2024-03-08 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| WO2018118887A1 (en) | 2016-12-22 | 2018-06-28 | Wake Forest University Health Sciences | Sirp-gamma targeted agents for use in the treatment of cancer |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| DK3565579T3 (da) | 2017-01-05 | 2023-09-04 | Kahr Medical Ltd | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf |
| ES2916217T3 (es) | 2017-01-05 | 2022-06-29 | Kahr Medical Ltd | Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma |
| WO2018136659A1 (en) * | 2017-01-18 | 2018-07-26 | Nant Holdings Ip, Llc | Modulation of tumor cell susceptibility |
| SG11201908472VA (en) * | 2017-02-15 | 2019-10-30 | Univ California | Compositions and methods for activating nk cells |
| MX2020001309A (es) | 2017-08-02 | 2020-08-20 | Phanes Therapeutics Inc | Anticuerpos anti-cd47 y sus usos. |
| CN111511766B (zh) | 2017-10-13 | 2024-06-07 | Ose免疫疗法 | 修饰的抗SIRPa抗体及其应用 |
| BR112020017709A2 (pt) | 2018-03-13 | 2020-12-29 | Ose Immunotherapeutics | Anticorpo anti-sirpa humana, fragmento de ligação a antígeno do mesmo ou anticorpo modificado do mesmo, composição farmacêutica, uso de um polipeptídeo, métodos para preparar um anticorpo anti-sirpa humana v1, para aumentar a apresentação cruzada de um antígeno e para avaliar a probabilidade de eficácia de um tratamento, método in vitro ou ex vivo para avaliar a probabilidade de eficácia de um tratamento, e, combinação de compostos |
| WO2019183266A1 (en) | 2018-03-21 | 2019-09-26 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
| CR20200566A (es) | 2018-05-25 | 2021-02-19 | Alector Llc | Anticuerpos anti-sirpa y metodos de utilización de los mismos |
| CN119868398A (zh) | 2018-06-14 | 2025-04-25 | 株式会社明治 | 用于促进免疫检查点抑制疗法的组合物 |
| CA3104780A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof |
| IL280102B1 (en) | 2018-07-11 | 2026-07-01 | Kahr Medical Ltd | Fusion protein containing PD1-4-1BBL and methods of using the same |
| SG11202102851XA (en) | 2018-09-27 | 2021-04-29 | Celgene Corp | SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN113166267A (zh) * | 2018-10-19 | 2021-07-23 | 俄亥俄州国家创新基金会 | 纳米工程化治疗性隐形细胞 |
| CA3141130A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
| EP3980747A1 (en) | 2019-06-07 | 2022-04-13 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| WO2021108693A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| JP2023528341A (ja) | 2020-06-01 | 2023-07-04 | エーエルエックス オンコロジー インコーポレイテッド | 低メチル化剤を含むがんを治療するための併用療法 |
| CN111808800B (zh) * | 2020-07-20 | 2022-08-26 | 中南大学湘雅二医院 | 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用 |
| WO2022120286A1 (en) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| EP4264265A4 (en) * | 2020-12-15 | 2024-11-13 | Agency for Science, Technology and Research | METHODS FOR CHARACTERIZING AN IMMUNOSUPPRESSIVE NEUTROPHIL |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| US20240368301A1 (en) | 2021-08-17 | 2024-11-07 | Hangzhou Jiuyuan Gene Engineering Co., Ltd | MONOCLONAL ANTIBODY TARGETING SIRPa AND USE THEREOF |
| CA3253030A1 (en) | 2022-06-01 | 2023-12-07 | ALX Oncology Inc. | Polytherapy for the treatment of urothelial carcinoma |
| WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
| CN115896015B (zh) * | 2023-02-08 | 2023-09-29 | 上海诚益生物科技有限公司 | 一种髓系来源抑制性细胞的体外培养方法 |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1048299A1 (en) | 1999-04-28 | 2000-11-02 | Faculteit der Geneeskunde van de Vrije Universiteit | Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| MX2010003642A (es) * | 2007-10-12 | 2010-08-09 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
| PT3056515T (pt) * | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| DK2429574T3 (da) | 2009-05-15 | 2015-06-22 | Univ Health Network | Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen |
| GB201015765D0 (en) * | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| WO2012149416A2 (en) * | 2011-04-28 | 2012-11-01 | University Of Southern California | Human myeloid derived suppressor cell cancer markers |
| WO2013056352A1 (en) * | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| EP3766511A1 (en) | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
| SG10201706383XA (en) * | 2013-02-06 | 2017-09-28 | Inhibrx Lp | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| WO2015138600A2 (en) | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
-
2014
- 2014-10-24 EP EP14190370.8A patent/EP3012271A1/en not_active Withdrawn
-
2015
- 2015-10-21 ES ES15794641T patent/ES2817074T3/es active Active
- 2015-10-21 ES ES20177260T patent/ES3060595T3/es active Active
- 2015-10-21 US US15/518,803 patent/US20170247464A1/en not_active Abandoned
- 2015-10-21 WO PCT/IB2015/058124 patent/WO2016063233A1/en not_active Ceased
- 2015-10-21 PL PL15794641T patent/PL3209691T3/pl unknown
- 2015-10-21 HU HUE15794641A patent/HUE050318T2/hu unknown
- 2015-10-21 CA CA2964203A patent/CA2964203C/en active Active
- 2015-10-21 DK DK15794641.9T patent/DK3209691T3/da active
- 2015-10-21 EP EP15794641.9A patent/EP3209691B1/en not_active Revoked
- 2015-10-21 JP JP2017520986A patent/JP6918279B2/ja active Active
- 2015-10-21 DK DK20177260.5T patent/DK3783027T3/da active
- 2015-10-21 EP EP25219878.3A patent/EP4691569A3/en active Pending
- 2015-10-21 PL PL20177260.5T patent/PL3783027T3/pl unknown
- 2015-10-21 EP EP20177260.5A patent/EP3783027B1/en active Active
-
2021
- 2021-06-21 JP JP2021102148A patent/JP7253008B2/ja active Active
-
2022
- 2022-05-20 US US17/749,856 patent/US20220281993A1/en not_active Abandoned
-
2023
- 2023-03-24 JP JP2023047480A patent/JP2023078398A/ja active Pending
-
2024
- 2024-04-25 US US18/645,607 patent/US20240294659A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response | |
| Gottstein et al. | Susceptibility versus resistance in alveolar echinococcosis (larval infection with Echinococcus multilocularis) | |
| Khammari et al. | Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones | |
| MX2019005125A (es) | Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular. | |
| Conti et al. | Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB‐neuT Mice | |
| Pircher et al. | Neoadjuvant chemo-immunotherapy modifies CD4+ CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients | |
| JP2009525478A5 (enExample) | ||
| EP4335931A3 (en) | Therapeutic and diagnostic methods for cancer | |
| JP2013539857A5 (enExample) | ||
| MX2023001945A (es) | Composiciones y metodos para el cribado de tumores solidos. | |
| WO2007071389A1 (en) | Method for treating disseminated cancer | |
| EA201591219A1 (ru) | Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение | |
| WO2019079624A3 (en) | Msi from liquid biopsies | |
| Costa et al. | Diagnosis of human strongyloidiasis: Application in clinical practice | |
| WO2021150936A1 (en) | Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer | |
| He et al. | TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: a meta-analysis | |
| MX2017013177A (es) | Anticuerpo anti-vegfr2 humano para terapia del cancer anti-angiogenica y dirigida. | |
| Stefanovic et al. | Adoptive immunotherapy of metastatic breast cancer: present and future | |
| WO2020081579A8 (en) | Monoclonal antibodies against human dickkopf3 and uses thereof | |
| Woller et al. | Virus infection, inflammation and prevention of cancer | |
| Goto et al. | DSP-7888, a novel cocktail design of WT1 peptide vaccine, and its combinational immunotherapy with immune checkpoint-blocking antibody against PD-1 | |
| Cachot et al. | 545 Tumor-specific cytolytic CD4 T cells mediate protective immunity against human cancer | |
| CN116940378A (zh) | 神经内分泌癌的治疗 | |
| Jacobsen et al. | 544 Multiomic characterization of T-cell populations at the single-cell level utilizing sensitive dextramers and BD® AbSeq on the BD RhapsodyTM Single-Cell Analysis system | |
| Hammitzsch et al. | AB0022 comparison of in vitro effects of kinase and epigenetic inhibitors on TH17 responses in inflammatory arthritis |